{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:50:09Z","timestamp":1792000209544,"version":"4.4.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009397","name":"Medizinischen Fakult\u00e4t, Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"publisher","award":["2729-0-0"],"award-info":[{"award-number":["2729-0-0"]}],"id":[{"id":"10.13039\/501100009397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["Transpl Int"],"abstract":"<jats:p>In this longitudinal observational study, we measured urinary glucose concentration, body composition and volume status (bioimpedance spectroscopy) and plasma renin and aldosterone concentrations in <jats:italic>n<\/jats:italic> = 22 kidney transplant recipients (KTRs) initiating on SGLT2I at baseline (BL), and after 1\u00a0week and 1, 3, and 6\u00a0months. Estimated glomerular filtration rate (eGFR) decreased by \u22122\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup> (IQR \u221210\u20130) after 1\u00a0week and remained stable thereafter. Urinary glucose concentration was 10 (3\u201324) g\/g creatinine after 1\u00a0week and correlated with eGFR (r<jats:sup>2<\/jats:sup> = 0.273; <jats:italic>p<\/jats:italic> = 0.057). SGLT2I did not affect HbA1c, fasting blood glucose, body weight, fat or lean mass. SGLT2I decreased fluid overload dependent on baseline overhydration (OH, r<jats:sup>2<\/jats:sup> = 0.54, <jats:italic>p<\/jats:italic> = 0.0003) without occurrence of dehydration. Plasma aldosterone increased at day 7, while plasma renin did not change significantly. In conclusion, SGLT2I corrected fluid overload in patients with elevated overhydration at baseline, while in euvolemic KTRs fluid status remained stable without reduction of body water below the reference range, thus promoting the safety of SGLT2I therapy in patients following kidney transplantation. Glucosuria, together with effects of SGLT2I on blood glucose control and body weight, is attenuated in KTRs dependent on eGFR.<\/jats:p>","DOI":"10.3389\/ti.2024.12879","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T18:36:09Z","timestamp":1718130969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["SGLT2 Inhibitors Correct Fluid Overload in Adult Kidney Transplant Recipients\u2014A Prospective Observational Study"],"prefix":"10.3389","volume":"37","author":[{"given":"Anja","family":"Schork","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Luise","family":"Eberbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruh","family":"Artunc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard N.","family":"Bohnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Eisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Heister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Vosseler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Nadalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas L.","family":"Birkenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Heyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Guthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients","volume":"9","year":"2009","journal-title":"Am J Transpl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 Inhibitors on Body Composition, Fluid Status and Renin-Angiotensin-Aldosterone System in Type 2 Diabetes: A Prospective Study Using Bioimpedance Spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc diabetology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 Inhibitors on Body Composition in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1159\/000510649","article-title":"Overhydration Measured by Bioimpedance Spectroscopy and Urinary Serine Protease Activity Are Risk Factors for Progression of Chronic Kidney Disease","volume":"45","author":"Schork","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000535643","article-title":"SGLT2 Inhibitors Decrease Overhydration and Proteasuria in Patients with Chronic Kidney Disease: A Longitudinal Observational Study","volume":"49","author":"Schork","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1287066","DOI":"10.3389\/fmed.2023.1287066","article-title":"Fluid Homeostatic Action of Dapagliflozin in Patients with Chronic Kidney Disease: The DAPA-BODY Trial","volume":"10","author":"Oka","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20420188221090001","DOI":"10.1177\/20420188221090001","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Kidney Transplant Recipients: What Is the Evidence?","volume":"13","author":"Ujjawal","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e14922","DOI":"10.1111\/ctr.14922","article-title":"Sweet and Simple as Syrup: A Review and Guidance for Use of Novel Antihyperglycemic Agents for post-Transplant Diabetes Mellitus and Type 2 Diabetes Mellitus after Kidney Transplantation","volume":"37","author":"Lawrence","year":"2023","journal-title":"Clin Transpl"},{"key":"B11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in Posttransplantation Diabetes Mellitus: A Prospective, Interventional Pilot Study on Glucose Metabolism, Fluid Volume, and Patient Safety","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transpl"},{"key":"B12","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","article-title":"Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases","volume":"51","author":"Attallah","year":"2019","journal-title":"Transpl Proc"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and Safety of Canagliflozin in Kidney Transplant Patients","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"gfz103","DOI":"10.1093\/ndt\/gfz103.sp770","article-title":"SP770 Sodium\/glucose Cotransporter 2 Inhibotor for the Treatment of Diabetes in Kidney Transplant Patients","volume":"34","author":"Kong","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.transproceed.2019.11.007","article-title":"Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients","volume":"52","author":"AlKindi","year":"2020","journal-title":"Transpl Proc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e00185","DOI":"10.1002\/edm2.185","article-title":"Early Initiation of Sodium-Glucose Linked Transporter Inhibitors (SGLT-2i) and Associated Metabolic and Electrolyte Outcomes in Diabetic Kidney Transplant Recipients","volume":"4","author":"Song","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and Safety of Empagliflozin in Renal Transplant Recipients with Posttransplant Diabetes Mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/ckj\/sfad007","article-title":"Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Kidney Transplant Patients with Type 2 or post-transplant Diabetes: An Observational Multicentre Study","volume":"16","author":"S\u00e1nchez Fructuoso","year":"2023","journal-title":"Clin Kidney J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2215\/CJN.12411212","article-title":"Bioimpedance-Guided Fluid Management in Hemodialysis Patients","volume":"8","author":"Moissl","year":"2013","journal-title":"Clin J Am Soc Nephrol : CJASN"},{"key":"B23","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1088\/0967-3334\/27\/9\/012","article-title":"Body Fluid Volume Determination via Body Composition Spectroscopy in Health and Disease","volume":"27","author":"Moissl","year":"2006","journal-title":"Physiol Meas"},{"key":"B24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ajcn\/85.1.80","article-title":"A Whole-Body Model to Distinguish Excess Fluid from the Hydration of Major Body Tissues","volume":"85","author":"Chamney","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41581-020-00350-x","article-title":"Organ protection by SGLT2 Inhibitors: Role of Metabolic Energy and Water Conservation","volume":"17","author":"Marton","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water Conservation Overrides Osmotic Diuresis during SGLT2 Inhibition in Patients with Heart Failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"814074","DOI":"10.3389\/fendo.2021.814074","article-title":"The Urinary Glucose Excretion by Sodium-Glucose Cotransporter 2 Inhibitor in Patients with Different Levels of Renal Function: A Systematic Review and Meta-Analysis","volume":"12","author":"Hu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/00325481.2016.1169894","article-title":"Effects of Canagliflozin on Body Weight and Body Composition in Patients with Type 2 Diabetes over 104 Weeks","volume":"128","author":"Blonde","year":"2016","journal-title":"Postgrad Med"}],"container-title":["Transplant International"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.12879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T18:36:12Z","timestamp":1718130972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/ti.2024.12879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":28,"alternative-id":["10.3389\/ti.2024.12879"],"URL":"https:\/\/doi.org\/10.3389\/ti.2024.12879","relation":{},"ISSN":["1432-2277"],"issn-type":[{"value":"1432-2277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,10]]},"article-number":"12879"}}